Previous studies identify LARG as a key regulator of RhoA/ROCK signaling that promotes tumor cell migration and invasion.Further studies indicate that in highly invasive glioblastoma, LARG silencing inactivates RhoA/ROCK signaling, markedly reduces tumor cell viability, and enhances sensitivity to chemotherapeutics such as temozolomide, supporting LARG as a potential therapeutic target [26–28]. This evidence concerns the gene ARHGEF12 and glioblastoma.